enVVeno Medical Corp’s activist reporting persons now hold 0.00% after Braeden Lichti and Northstrive Fund II LP sold all their previously owned common stock. The amendment matters to investors because it ends the Schedule 13D position, with the document identifying the change as a final amendment and exit filing.
Key Highlights
- Northstrive Fund II LP sold its previously owned common stock from September 11, 2026 to September 14, 2026.
- Braeden Lichti is identified as Northstrive Fund II LP’s manager and as chief executive officer of Northstrive Companies Inc.
- Lichti used personal funds for his purchases, while Northstrive Fund II LP used working capital.
EnVVeno Medical Corp (NASDAQ: NVNO) now has no shares held by activist reporting persons Braeden Lichti and Northstrive Fund II LP, leaving the reported position at 0.00%. The amendment identifies the change as a final amendment and exit filing for both parties.
Sales Leave No Reported Ownership
Northstrive Fund II LP completed sales of its previously owned common stock from September 11, 2026 to September 14, 2026. The stock carries a Par Value of $0.00001 per share. The amendment lists zero sole and shared power to vote or direct votes for Northstrive Fund II LP, alongside zero sole and shared power to dispose of or direct disposition of shares.
Final Amendment Closes Activist Position
The shares were held by Northstrive Fund II LP and Lichti. Lichti is the fund’s manager and is principally engaged as chief executive officer of Northstrive Companies Inc. while Northstrive Fund II LP invests in private and public securities. Lichti used personal funds to buy his shares, and the fund used Working Capital for its purchases. Lichti and the fund signed the amendment on September 15, 2026.
FAQs
Q: What happened to Braeden Lichti’s enVVeno Medical Corp shares?
A: Braeden Lichti sold all previously owned common stock on September 11, 2026. His reported position is now 0.00%, and he owns no shares.
Q: How does the enVVeno Medical Corp activist stake amendment affect ownership reporting?
A: The amendment is identified as a final Schedule 13D amendment and exit filing for Lichti and Northstrive Fund II LP. Both report no remaining common-stock ownership.
Q: When did Northstrive Fund II LP sell its enVVeno Medical Corp shares?
A: Northstrive Fund II LP sold all previously owned common stock from September 11, 2026 to September 14, 2026. Braeden Lichti signed for the fund on September 15, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.